Advertisement
JNJ or PRAX or ZTS
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Praxis Precision Medicines (PRAX) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- JNJ has delivered strong YTD gains of around 18%, driven by oncology approvals and pipeline expansions, outperforming broader markets.
- PRAX shows explosive longer-term growth with over 700% one-year returns, fueled by NDA filings for CNS therapies, though recent weeks have been volatile.
- ZTS trades at a relatively attractive P/E of about 20x amid recent share weakness, supported by steady revenue and acquisitions in animal health.
- JNJ offers stability as a diversified healthcare giant, contrasting PRAX's high-risk biotech profile and ZTS's niche focus.
- Recent momentum favors JNJ for consistency, while PRAX leads in growth potential amid clinical catalysts.
- Valuation sensitivity highlights ZTS's relative affordability versus peers in healthcare stock comparison.
Introduction
This stock comparison examines JNJ, a healthcare conglomerate; PRAX, a CNS-focused biotech; and ZTS, the leading animal health provider. These stocks span human pharmaceuticals, precision neuroscience, and veterinary care, offering insights into relative performance amid sector rotations. Traders seeking stability may eye JNJ, growth chasers PRAX, and value in niche markets ZTS. Recent market positioning reflects pipeline progress, acquisitions, and economic pressures, aiding decisions in volatile conditions.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) operates in innovative medicine and MedTech, emphasizing oncology, immunology, and cardiovascular therapies. Recent weeks have seen positive momentum from EU approval for Akeega in prostate cancer and U.S. FDA clearance for a blood cancer drug under speedy review. Stock behavior reflects YTD gains near 18%, outpacing the S&P 500, with one-year returns exceeding 50%. Sentiment shifts stem from pipeline advancements and analyst price target hikes, though minor pullbacks occurred amid broader market activity. Trading around $243, JNJ maintains stability through diversified revenue exceeding $94 billion annually.
PRAX Overview and Recent Performance
Praxis Precision Medicines (PRAX) is a clinical-stage biopharma developing therapies for CNS disorders like epilepsy and essential tremor via small molecules and ASOs. Key recent developments include NDA preparations for ulixacaltamide and relutrigine, both with FDA Breakthrough Therapy Designation, and a $1.5 billion cash runway into 2028. Shares have surged over 700% in the past year, driven by clinical data and investor buys, though recent market activity shows volatility with flat 30-day returns around $300. Performance reflects high growth potential tempered by biotech risks, with analyst targets suggesting upside.
ZTS Overview and Recent Performance
Zoetis (ZTS) leads global animal health, offering medicines, vaccines, and diagnostics for companion and livestock animals across 100+ countries. Recent activity includes a $160 million acquisition of Neogen's genomics business and Q4 earnings beats, with revenue near $9.5 billion. Shares have faced pressure, down over 20% in the past year to around $120, lagging peers amid demand concerns for products like Librela, though YTD up modestly at 4%. Sentiment is influenced by strategic expansions and steady growth forecasts of 4-5% revenue.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from hundreds available, which collectively trade thousands of tickers using diverse strategies like swing trading, pattern recognition, and sector rotation across timeframes from minutes to weeks. Only bots excelling in current conditions—such as volatility in semis, energy, and biotech—earn trending status, with stats like annualized returns up to 132%, win rates of 60-80%, and profit factors of 2.0-3.8. Examples include semiconductor bots at +90-100% returns and aerospace at +65% with low drawdowns. These virtual agents provide real-time signals for copy trading, adapting to market shifts. Explore Trending AI Robots to identify suitable options for your portfolio.
Head-to-Head Comparison
JNJ’s broad business model contrasts PRAX’s focused CNS pipeline and ZTS’s animal health niche, with JNJ revenue dwarfing peers at $94B versus ZTS’s $9.5B and PRAX’s pre-revenue status. Growth drivers include PRAX’s NDAs for rare epilepsies, JNJ’s oncology catalysts, and ZTS’s acquisitions. Recent momentum favors JNJ’s steady gains over ZTS’s weakness, while PRAX excels longer-term. Risks: PRAX’s trial failures versus JNJ’s litigation and ZTS’s demand sensitivity. Sector exposure ties all to healthcare, but ZTS offers P/E appeal at 20x versus higher multiples elsewhere; sentiment leans stable for JNJ.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ for its trend consistency, YTD outperformance, and catalyst-rich pipeline in a volatile market. While PRAX shows superior relative growth potential and ZTS valuation edge, JNJ’s stability and positioning suggest higher probability of near-term upside across scenarios.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- PRAX’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 6 bearish.
- PRAX’s TA Score: 5 bullish, 4 bearish.
- ZTS’s TA Score: 4 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -1.79% price change this week, while PRAX (@Biotechnology) price change was +8.34% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
JNJ is expected to report earnings on Jul 22, 2026.
PRAX is expected to report earnings on May 13, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| JNJ | PRAX | ZTS | |
| Capitalization | 564B | 9.54B | 51.5B |
| EBITDA | 41.1B | -326.06M | 4.07B |
| Gain YTD | 13.759 | 16.204 | -2.319 |
| P/E Ratio | 21.23 | N/A | 20.33 |
| Revenue | 94.2B | 0 | 9.47B |
| Total Cash | 20.1B | 599M | 2.31B |
| Total Debt | 47.9B | 110K | 9.24B |
JNJ | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 11 | 100 | |
SMR RATING 1..100 | 27 | 16 | |
PRICE GROWTH RATING 1..100 | 45 | 62 | |
P/E GROWTH RATING 1..100 | 41 | 85 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (26) in the Pharmaceuticals Major industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew similarly to ZTS’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew significantly faster than ZTS’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as ZTS (62) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew similarly to ZTS’s over the last 12 months.
JNJ's P/E Growth Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that JNJ’s stock grew somewhat faster than ZTS’s over the last 12 months.
| JNJ | PRAX | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 42% | 2 days ago 90% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 52% | 2 days ago 90% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 32% | 2 days ago 90% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 40% | 2 days ago 86% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 88% | 2 days ago 54% |
| Advances ODDS (%) | 10 days ago 44% | 5 days ago 84% | 5 days ago 52% |
| Declines ODDS (%) | 2 days ago 41% | 3 days ago 84% | 3 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 86% | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 38% | 2 days ago 86% | 2 days ago 61% |
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | +6.90% | ||
| BEAM - PRAX | 40% Loosely correlated | +3.49% | ||
| BHVN - PRAX | 37% Loosely correlated | +9.69% | ||
| RAPP - PRAX | 35% Loosely correlated | +0.58% | ||
| VERU - PRAX | 35% Loosely correlated | -1.21% | ||
| RXRX - PRAX | 35% Loosely correlated | +5.00% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 52% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||